Retatrutide has emerged as a new treatment in the fight against obesity. This groundbreaking drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By boosting these receptors, Retatrutide reduces hunger pangs, {promotesglucose regulation, and ultimately leads to significant slimming. While studies